Simcere Pharmaceutical Group (STU:S2P) Total Equity: €1,141.5 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:S2P Simcere Pharmaceutical Group Ltd STU:S2P
94 GF Score
Price €1.38
GF Value €1.16
View Full Analysis

What is Simcere Pharmaceutical Group Total Equity?

Simcere Pharmaceutical Group STU:S2P -2.82% 94 Total Equity is €1,141.5 Mil as of Dec. 2025. GuruFocus rates STU:S2P with a GF Score™ of 94/100 and a GF Value™ of €1.16.

Simcere Pharmaceutical Group's total equity for the quarter that ended in Dec. 2025 was €1,141.5 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Simcere Pharmaceutical Group Total Equity Historical Data

* Premium members only.

The historical data trend for Simcere Pharmaceutical Group's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Simcere Pharmaceutical Group Total Equity Chart

Simcere Pharmaceutical Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only 897.99 967.84 927.60 935.74 1,141.54

Simcere Pharmaceutical Group Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 927.60 884.70 935.74 873.50 1,141.54
STU:S2P
94GF Score
Simcere Pharmaceutical Group Ltd STU:S2P
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Simcere Pharmaceutical Group Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Simcere Pharmaceutical Group's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1785.508-643.973
=1,141.5

Simcere Pharmaceutical Group's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1785.508-643.973
=1,141.5

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €1,141.5 Mil mean?
Simcere Pharmaceutical Group (STU:S2P) has a Total Equity of €1,141.5 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Simcere Pharmaceutical Group and its competitors.
Is Simcere Pharmaceutical Group's Total Equity too high?
Simcere Pharmaceutical Group's current Total Equity is €1,141.5 Mil. Overall, Simcere Pharmaceutical Group has a GF Score™ of 94/100, reflecting its overall financial health beyond just this single metric.
How does Simcere Pharmaceutical Group's Total Equity compare to ZTS and UTHR?
Simcere Pharmaceutical Group's Total Equity of €1,141.5 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Simcere Pharmaceutical Group and its competitors. Simcere Pharmaceutical Group's current Total Equity is €1,141.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simcere Pharmaceutical Group stock overvalued right now?
Simcere Pharmaceutical Group (STU:S2P) has a current Total Equity of €1,141.5 Mil. The stock's GF Value™ is €1.16, compared to a current price of €1.38 — trading 19% above its estimated fair value. The current Total Equity is €1,141.5 Mil. Simcere Pharmaceutical Group's overall GF Score™ is 94/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Simcere Pharmaceutical Group (STU:S2P), the current Total Equity is €1,141.5 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Simcere Pharmaceutical Group (STU:S2P) Overvalued in 2026?

Based on GuruFocus' analysis, Simcere Pharmaceutical Group stock appears to be overvalued. The current stock price of €1.38 is trading 19% above its estimated GF Value™ of €1.16.

Key valuation signals for STU:S2P:

  • Total Equity: €1,141.5 Mil
  • GF Value™: €1.16 vs. price of €1.38 (19% above fair value)
  • GF Score™: 94/100

No single metric tells the full story. See the STU:S2P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Simcere Pharmaceutical Group Business Description

Other Exchanges 02096:Hong Kong
Address No. 699-18, Xuanwu Road, Xuanwu District, Jiangsu Province, Nanjing, CHN, 210042
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. The company has a diversified product portfolio focused on therapeutic areas, including, neuroscience, anti-oncology, autoimmune, and antiinfection. The company's products include Endostar, Enweida, Enzeshu, Iremod, Quviviq, Cosela, Sanbexin and Others.
94GF Score

Get the complete analysis for STU:S2P

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.38
Price
€1.16
GF Value